Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.
Bevacizumab is a full-length humanized murine monoclonal anti-VEGF (vascular endothelial growth factor) IgG1 antibody that was approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer. The intravenous formulation of bevacizumab was first injected intravitreally in 2005 and has proven to be a relatively safe and extremely effective off-label treatment for neovascular ocular disease and diseases associated with macular edema. This paper is a review of the ophthalmic uses of bevacizumab in processes other than choroidal neovascularization.
Department of Ophthalmology, Saint Louis University, Saint Louis, Missouri 63104, USA.
Andrew J
AJ
Barkmeier
Levent
L
Akduman
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005128:Eye Diseases / Q000188:drug therapy*; D018463:Filtering Surgery / Q000009:adverse effects; D005901:Glaucoma / Q000601:surgery; D015355:Glaucoma, Neovascular / Q000188:drug therapy; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D011183:Postoperative Complications / Q000188:drug therapy; D012170:Retinal Vein Occlusion / Q000188:drug therapy; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab